Fig. 3: The potent antitumor effect of M1-mutIL-18 in multiple solid tumors. | Nature Communications

Fig. 3: The potent antitumor effect of M1-mutIL-18 in multiple solid tumors.

From: Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction

Fig. 3

a−l Female C57BL/6 J or BALB/c mice aged 4−6 weeks were implanted with B16F10 cells (a, b) EMT6 cells (c, d) GL261 cells (e, f), B16F10 cells (g, h) MC38 cells (i, j) or CT26 cells (k, l) and treated with M1 (1.5 × 107 PFU) or M1-mutIL-18 (1.5 × 107 PFU) when the tumors reached the appropriate volume as shown in the figure. M1 or M1-mutIL-18 were administered via tail vein injection for 5 consecutive days. m−r, Mice re-challenged with twice the initial dose of CT26 tumor cells after successful M1-mutIL-18 treatment. m, n Mice were re-challenged on the ipsilateral of the cured site 126 days after initial tumor inoculation. o, p Mice were re-challenged on the contralateral of the cured site 115 days after initial tumor inoculation. q, r Mice were re-challenged on the ipsilateral of the cured site 487 days after initial tumor inoculation. a−r the number of mice is shown in the figure. In all figures, data with error bars represent mean ± SD. P-values were calculated using unpaired, two-tailed Student’s t-test (a−q) or log rank test (d−r).

Back to article page